These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 15250019)

  • 1. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
    Martino R; Viscoli C
    Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febrile neutropenia in haematological malignancies.
    Sharma A; Lokeshwar N
    J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ; MacDougall C; Gallagher JC
    Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical antifungal therapy.
    Klastersky J
    Int J Antimicrob Agents; 2004 Feb; 23(2):105-12. PubMed ID: 15013034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fungal infections in neutropenic cancer patients.
    Parvez T
    J Coll Physicians Surg Pak; 2003 Nov; 13(11):669-73. PubMed ID: 14700501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida infections in non-neutropenic children after the neonatal period.
    Hacimustafaoglu M; Celebi S
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):923-40. PubMed ID: 21973304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Sugar AM
    Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial prophylaxis in febrile neutropenia.
    Yoshida M; Ohno R
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S65-7. PubMed ID: 15250025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
    Imhof A; Walter RB; Schaffner A
    Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients].
    Zielińska E
    Przegl Epidemiol; 2003; 57(2):299-307. PubMed ID: 12910598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.